ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

Zometa Can Reduce Risk Of Skeletal-Related Events

August 26, 2011

NCAB Approves New Pancreatic Cancer Project, Hears Favorable Reports On Organ site Programs

November 29, 1974

NCI Considering Combining Support, Control Core Grants; Directors Reject Two Grants, One Review

June 2, 1978

AACR Calls For Clear Statement; Says Report Was “Premature”

February 14, 1997

Program Announcement On Effects Of Low Dose Radiation

October 2, 1981

Study: Negative HPV Test More Accurate than Negative Pap Test In Predicting Cervical Cancer Risk

July 25, 2014